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Background—Alterations in cardiac energy metabolism downstream of neurohormonal stimulation play a crucial role in
the pathogenesis of heart failure. The chronic adrenergic stimulation that accompanies heart failure is a signaling
abnormality that leads to the upregulation of G protein–coupled receptor kinase 2 (GRK2), which is pathological in the
myocyte during disease progression in part owing to uncoupling of the -adrenergic receptor system. In this study, we
explored the possibility that enhanced GRK2 expression and activity, as seen during heart failure, can negatively affect
cardiac metabolism as part of its pathogenic profile.
Methods and Results—Positron emission tomography studies revealed in transgenic mice that cardiac-specific overex-
pression of GRK2 negatively affected cardiac metabolism by inhibiting glucose uptake and desensitization of insulin
signaling, which increases after ischemic injury and precedes heart failure development. Mechanistically, GRK2
interacts with and directly phosphorylates insulin receptor substrate-1 in cardiomyocytes, causing insulin-dependent
negative signaling feedback, including inhibition of membrane translocation of the glucose transporter GLUT4. This
identifies insulin receptor substrate-1 as a novel nonreceptor target for GRK2 and represents a new pathological
mechanism for this kinase in the failing heart. Importantly, inhibition of GRK2 activity prevents postischemic defects
in myocardial insulin signaling and improves cardiac metabolism via normalized glucose uptake, which appears to
participate in GRK2-targeted prevention of heart failure.
Conclusions—Our data provide novel insights into how GRK2 is pathological in the injured heart. Moreover, it appears
to be a critical mechanistic link within neurohormonal crosstalk governing cardiac contractile signaling/function through
-adrenergic receptors and metabolism through the insulin receptor. (Circulation. 2011;123:1953-1962.)
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Despite improvements in the treatment of heart failure(HF), the prognosis of this disease remains poor.1,2 The
reason that HF continues to worsen even in patients receiving
optimal therapy is unclear; however, there is increasing
evidence that perturbations in cardiac metabolism can con-
tribute to the progression of cardiomyopathy and to a loss of
pharmacological effectiveness.3,4 Therefore, approaches tar-
geting more efficient substrate use and preservation of car-
diac metabolism are attractive therapeutic strategies.5 In the
adult heart, the major pathway for ATP production is fatty
acid oxidation,6,7 whereas the relative contribution of glucose
increases during stress or injury such as during exercise or
ischemia.5 During HF, there are excessive uptake and myo-
cardial free fatty acid accumulation with reduced glucose
use.8,9 In animal models of HF and in human disease, these
metabolic alterations reduce myocardial oxygen efficiency
and lead to a depletion of intracellular ATP.10,11
Clinical Perspective on p 1962
Insulin receptor signaling is critically involved in increas-
ing glucose uptake in the myocardium, and cardiac insulin
resistance contributes to the development of left ventricular
(LV) dysfunction by reducing cardiac efficiency through
metabolic shift toward fatty acids use.12 Indeed, a profound
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state of insulin resistance has been found in the hearts of
ob/ob mice, and the ability of these hearts to modulate
substrate use in response to insulin and changes in fatty acid
supply is altered.13 Importantly, normalization of cardiac
metabolism by overexpressing a human GLUT4 transgene in
mice with insulin resistance recovered the altered cardiac
function observed in these animals.14,15 Therefore, these
studies indicate that cardiac insulin resistance reduces the
metabolic efficiency of the heart, which can lead to contrac-
tile dysfunction. Moreover, insulin resistance is a known and
recognized phenomenon leading to HF,16 as seen in positron
emission tomographic (PET) studies showing that failing
human myocardium has reduced glucose uptake and in-
creased free fatty acid uptake.17
Several hypotheses have been proposed to explain the
association between altered cardiac metabolism, insulin re-
sistance, and HF. Among these hypotheses, there is a strong
correlation with neurohormonal activation,18,19 which in-
creases plasma free fatty acid levels and inhibits insulin
receptor signaling, resulting in a loss of myocyte glucose
uptake.20 An important abnormality in the myocyte induced
by neurohormonal activation in HF is the upregulation of G
protein–coupled receptor kinase 2 (GRK2), which classically
phosphorylates activated G protein–coupled receptors such
as the -adrenergic receptors (ARs) in the heart, leading to
attenuated signaling.21 In human HF, increased GRK2 is
associated with lower cardiac function and prognosis.22,23
Recent evidence suggests that GRK2 can have non–G
protein–coupled receptor effects, including playing an uniden-
tified role in the regulation of insulin signaling in noncardiac
cells.24,25 Moreover, increases in GRK2 activity after AR
stimulation inhibit insulin-dependent glucose extraction.26
Therefore, we hypothesized that increased levels of GRK2, as
seen during HF, directly induce myocardial insulin resistance,
and given the importance of cardiac signaling for efficient
metabolic substrate use, we have studied the role of GRK2 in
regulating cardiac insulin signaling and metabolism in normal
and postischemic myocytes and hearts. Our data reveal a role for
GRK2 in HF pathogenesis that extends beyond the known
negative effects on AR signaling and cardiac contractility by
demonstrating that GRK2 can critically and negatively affect
cardiac insulin signaling and metabolism.
Methods
Experimental Procedures
Experimental procedures were performed essentially as described
previously.27,28 An expanded Methods section appears in the online-
only Data Supplement.
Statistical Analyses
All experiments were performed at least in triplicate using cell
isolates from different rats. The results were expressed as
meanSEM. We used Prism 4 and SPSS 17 to perform statistical
analysis with a 2-tailed Student t test for in vitro studies and 2-way
and repeated measures ANOVA with a Bonferroni posthoc test for
the in vivo studies. SPSS was used to evaluate the normal distribution
according to the Levene test for normality and to provide different P
values for unpaired samples, depending on normal distribution. Even
when the data are not normally distributed, we still found significant
differences between means of different treatments and/or groups. A
value of P0.05 was considered statistically significant.
Results
G Protein–Coupled Receptor Kinase 2 Levels
Influence In Vivo Cardiac Glucose Uptake
We first examined whether increased GRK2 in cardiomyo-
cytes can alter in vivo glucose uptake in the hearts of mice
after insulin treatment. This is important because myocardial
GRK2 upregulation occurs immediately after ischemic in-
jury29 and may trigger further signaling defects. Therefore,
we performed micro-PET using 18-fluorodeoxyglucose (18-
FDG) in transgenic mice with cardiac-specific GRK2 over-
expression (Tg-GRK230) and their nontransgenic littermate
controls (NLCs). An insulin injection produces a robust
increase in in vivo 18-FDG accumulation in the hearts of
NLC mice, which is significantly lower in Tg-GRK2 mice
(Figure 1A). Mechanistically, GRK2 enhancement appears to
cause a loss of insulin-dependent GLUT4 membrane translo-
cation (Figure 1B).
G Protein–Coupled Receptor Kinase 2 Regulation
of Insulin Signaling in Cardiomyocytes
Because of the above provocative in vivo results, we explored
molecular mechanisms involving GRK2 and insulin signaling
in cultured adult rat ventricular cardiomyocytes (ARVMs).
As expected, when ARVMs were exposed to insulin, GLUT4
membrane translocation was induced, as was the activation of
the downstream kinase, Akt (Figure 2A through 2C). Unex-
pectedly, we found that insulin induced the membrane
translocation of GRK2 (Figure 2A and 2D). The cause of
GRK2 membrane translocation after insulin administration
is unclear, but we next evaluated whether increased mem-
brane GRK2 levels could alter downstream insulin recep-
tor signaling. To do this, we prestimulated ARVMs with
the AR agonist isoproterenol to cause G-dependent
GRK2 translocation, which was evident in ARVMs (Figure
2A and 2). Interestingly, after isoproterenol pretreatment,
insulin failed to induce GLUT4 translocation, and there
was significantly less insulin-dependent Akt activation
(Figure 2A through 2C).
To further explore how GRK2 levels may alter myocyte
insulin signaling, we overexpressed GRK2 in ARVMs using
an adenovirus (AD; ADGRK2). We found that increased
GRK2 in ARVMs attenuated insulin-stimulated Akt activa-
tion and GLUT4 membrane translocation compared with
control myocytes infected with AD green fluorescent protein
(GFP; Figure 3A and 3B). Reduced GLUT4 translocation is
consistent with the above findings in Tg-GRK2 mice showing
that enhanced GRK2 can lead to a loss of insulin-dependent
in vivo cardiac glucose uptake. Indeed, we found that
insulin-dependent [H3]-deoxyglucose uptake in ARVMs was
significantly attenuated by ADGRK2 (Figure 3C).
G Protein–Coupled Receptor Kinase 2 Activity Is
Required for Attenuation of Cardiomyocyte
Insulin Signaling via Direct Phosphorylation of
Insulin Receptor Substrate-1
Mechanistically, GRK2 could exert its inhibitory effect on
insulin-dependent GLUT4 translocation and cardiomyocyte
glucose uptake and metabolism through different pathways.
GLUT4 membrane translocation has been shown to be
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dependent on Gq/11 signaling,25 and GRK2 has a known
RGS domain within its aminoterminus that can interact
directly with Gq and inhibit its activity. Furthermore, GRK2
has recently been shown to interact with and inhibit Akt in
endothelial cells.31 We conducted experiments to test these
possible mechanisms and found no evidence that GRK2
interacted with either of these proteins in ARVMs, either
basally or after stimulation of cells with insulin (data not
shown). Therefore, we explored the possibility that GRK2
could regulate insulin signaling in cardiomyocytes in other
ways. Of note, kinase activity of GRK2 was necessary for the
negative regulation of insulin signaling because the kinase-
dead (K220R) GRK2 dominant-negative mutant (GRK2DN)
failed to alter Akt activation (Figure 4A) and GLUT4
membrane translocation in response to insulin (Figure 4B).
We next focused our attention on a potential regulatory
role of GRK2 on insulin receptor substrate-1 (IRS1). This
molecule moves to the plasma membrane after insulin stim-
ulation and binds activated insulin receptors, leading to Tyr
phosphorylation and subsequent activation of downstream
signaling.21 The association of IRS1 with the insulin receptor
also initiates events that lead to the attenuation of the
Figure 1. G protein–coupled receptor
kinase 2 (GRK2) levels influence in vivo
cardiac glucose uptake. A, Transgenic
(Tg)-GRK2 and nontransgenic littermate
control (NLC) mice were studied by posi-
tron emission tomography to evaluate
cardiac glucose uptake after intraperito-
neal injection of insulin (Ins; 0.075 U/kg IP).
Insulin significantly increases glucose
uptake; however, this response was
attenuated in BK12 mice (*P0.05, Ins
vs basal; §P0.05, Tg-GRK2 vs NLC;
n8 per group). SUV indicates standard-
ized uptake values. B, Plasma mem-
brane GLUT4 protein levels from
Tg-GRK2 and NLC hearts. Animals were
injected with Ins as above and eutha-
nized 15 minutes later. The GLUT4 levels
on the plasma membrane were
increased by Ins in NLC but attenuated
in Tg-GRK2. The GLUT4 level was nor-
malized to the membrane protein G
(*P0.05, Ins vs basal; §P0.05, fold of
increased translocation to the mem-
brane, Tg-GRK2 vs NLC; n3 per
group).
Figure 2. Interplay between -adrenergic
receptor (AR and insulin receptor sig-
naling. Adult rat ventricular cardiomyo-
cytes were stimulated with insulin (Ins;
0.1 mol/L for 10 minutes) with or with-
out pretreatment with the AR agonist
isoproterenol (Iso; 10 mol/L for 5 min-
utes). Membrane fractions were pre-
pared and blotted for signaling proteins.
A, Representative Western blot showing
membrane GLUT4, phosphorylated (p)
Akt, and G protein–coupled receptor
kinase 2 (GRK2). G blotting was used
as loading control. B through D, Bar
graphs showing GLUT4 translocation
(*P0.05, Ins vs basal; n3; **PNS,
IsoIns vs Iso; n3 per group). Akt was
activated in response to Ins but attenu-
ated with Iso pretreatment (§P0.05,
fold activation, IsoIns vs Ins alone;
n3 per group) and GRK2 translocation
induced by Ins with or without Iso pre-
treatment (*§P0.05, Ins, Iso, and
IsoIns vs basal; n3 per group).
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biological effects of insulin32 through phosphorylation of
IRS1 at Ser307, which disrupts IRS1 binding to the insulin
receptor and promotes its proteasomal degradation.33 Of note,
when IRS1 is phosphorylated at Ser307, there is a reduction
in Tyr612 phosphorylation, and there appears to be a recip-
rocal relationship between these 2 sites of posttranslational
modification.24,33 A recent study has shown a physical inter-
action between GRK2 and IRS1 in adipocytes and muscle
cells under basal conditions, which is disrupted by insulin
treatment.34 However, our experiments in adult cardiac myo-
cytes show that both GRK2 and IRS1 translocate to the
plasma membrane. Moreover, they associate together, and
this interaction increases on insulin treatment of myocytes
(Figure IA and IB in the online-only Data Supplement).
Therefore, we pursued the hypothesis that increased GRK2
activity might enhance the feedback loop induced by insulin
via IRS1 inhibitory phosphorylation. We observed that over-
expression of GRK2 itself significantly increased Ser307
phosphorylation of IRS1 under basal conditions and after
insulin treatment compared with ADGFP-infected cells
(Figure 4C).
To address this potential specific role of GRK2 in myocyte
insulin signaling, we studied levels of phospho-Ser307 IRS1
in isolated cells from NLC, Tg-GRK2, and cardiac-specific
GRK2 knockout (KO) mice27 after insulin administration.
Figure 4D shows that increased cardiac GRK2 in Tg-GRK2
ARVMs results in increased basal and insulin-stimulated
IRS1 phospho-Ser307 levels, whereas GRK2KO myocytes
have attenuated insulin-stimulated phosphorylation of IRS1
at Ser307 compared with NLC myocytes. Importantly, an in
vitro kinase assay shows that purified GRK2 directly phos-
phorylates purified GST-IRS1 at Ser307 (Figure 4E). The
physiological relevance of GRK2 phosphorylation of Ser307
in insulin signaling regulation was explored by using an IRS1
in which Ser307 was mutated to alanine, which could not be
phosphorylated by GRK2 (Figure IC in the online-only Data
Supplement). Overexpression of this mutated IRS1 by ade-
novirus (ADIRS1mt) in neonatal rat ventricular cardiomyo-
cytes removes the ADGRK2 inhibitory effects on insulin-
mediated activation of Akt (Figure 4F) and GLUT4
translocation to the membrane (Figure ID in the online-only
Data Supplement).
Consistent with GRK2 activity inducing Ser307 phos-
phorylation of IRS1, an inhibitory phosphorylation, we
found that GRK2, but not the kinase-dead GRK2 mutant
(K220R), also reduced the stimulatory-signaling Tyr612
phosphorylation in ARVMs (Figure IE in the online-only
Data Supplement).
Figure 3. G protein–coupled receptor
kinase 2 (GRK2) overexpression in adult
rat ventricular cardiomyocytes (ARVMs)
inhibits cellular effects of insulin.
Adenovirus-infected ARVMs were
treated with or without 0.1 mol/L insu-
lin (Ins) for either 10 or 30 minutes. A,
Representative Western blot from ARVM
whole lysate. Insulin activation of Akt
was attenuated by GRK2 overexpres-
sion. Total Akt was blotted as loading
control (*P0.05, fold activation vs ade-
novirus [AD] green fluorescent protein
[GFP]; n3 per group). B, Western blot
from plasma membranes of ARVMs
showing increased GLUT4 translocation
in response to 0.1 mol/L Ins for 10
minutes with GFP overexpression but
blunted with GRK overexpression
(*P0.05 vs basal; **PNS vs basal;
n3). G was used as loading control.
C, ARVMs were stimulated with Ins at
concentrations ranging from 1 nmol/L to
10 mol/L for 10 minutes in the pres-
ence of ADGFP or ADGRK2 infection.
The rate of glucose uptake was deter-
mined by [H3]-deoxyglucose (*§P0.01
vs ADGFP; n3 per group).
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Figure 4. Mechanism of inhibitory effects of G protein–coupled receptor kinase 2 (GRK2) on insulin signaling in myocytes. A and B,
Adult rat ventricular cardiomyocytes (ARVMs) were infected with adenovirus (AD) green fluorescent protein (GFP), ADGRK2, or kinase-
dead GRK2 (ADGRK2DN) and stimulated with insulin (Ins; 0.1 mol/L for 10 minutes). A, Representative immunoblot (IB) in whole-cell
lysates showing reduced phosphorylated (p) Akt levels when GRK2 is overexpressed (*P0.01, fold activation vs ADGFP and
ADGRK2DN; n3 per group). B, Insulin-stimulated GLUT4 membrane levels in ARVMs are attenuated with GRK2 overexpression
(*P0.05 vs basal; **PNS vs basal; n3). C, Insulin receptor substrate-1 (IRS1) was immunoprecipitated (IP) from whole lysate of
ARVMs infected with adenovirus (AD) green fluorescent protein (GFP) or G protein-coupled receptor kinase 2 (ADGRK2) and stimulated
with insulin (Ins) as above. Top, Representative immunoblot for phosphorylated (p) Ser307 showing increased p-Ser307 with ADGRK2
treatment. Bottom, Total IRS1 (*P0.05 vs ADGFP; n3). D, Level of p-Ser307 of IRS1 was evaluated by immunoprecipitation of equal
amounts of IRS1 from isolated myocytes of nontransgenic littermate controls (NLC), transgenic (Tg)-GRK2, and cardiac GRK2 knockout
(KO) mice after stimulation with Ins (107 mol/L; 10 minutes). Representative blots for GRK2, p-Ser307, IRS1, and total (t) IRS1 are
shown. Reduced and increased levels of pSer307IRS1 were observed in GRK2KO and Tg-GRK2, respectively, vs NLC (*P0.01, fold of
activation, GRK2KO vs NLC; n3; **P0.01, Tg-GRK2 vs NLC; n3 per group). E, GRK2 phosphorylates IRS1 at Ser307. An in vitro
kinase assay was performed with purified GST-IRS1 alone (none) or in the presence of ATP or ATP plus purified GRK2. Representative
blot from 3 independent assays (top) and densitometric analysis (bottom) are shown (*P0.05, fold activation vs ATP and none). F,
Neonatal rat ventricular cardiomyocytes (NRVMs) were coinfected with either ADIRS1 wild type (wt) or ADIRS1 mutant Ser307Ala (mt) in
addition to ADGFP or ADGRK2 and stimulated with Ins as above. Representative immunoblot showing p-Akt levels is provided
(*P0.01, fold activation vs ADGRK2ADIRS1wt; n3 per group).
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Cardiac Glucose Uptake Defects Precede Heart
Failure Development After Myocardial
Infarction, and Both Are Augmented With
G Protein–Coupled Receptor
Kinase 2 Upregulation
With our findings that increased GRK2 levels in myocytes
negatively affect insulin signaling, we next sought to deter-
mine whether this translates to the pathogenesis of HF. To
determine whether GRK2-mediated loss of glucose metabo-
lism occurs in compromised myocardium, we used micro-
PET to follow 18-FDG uptake after myocardial infarction
(MI). Left coronary artery ligation induced a reproducible LV
infarct in Tg-GRK2, GRK2KO, and NLC mice, as previously
described27 (data not shown). All groups showed increased
18-FDG uptake 1 week after MI, consistent with the heart
increasing to the more protective glucose metabolism.5 How-
ever, the immediate post-MI glucose uptake response was
significantly reduced in Tg-GRK2 mice compared with NLC
(Figure 5A). Furthermore, a progressive reduction in glucose
uptake after MI is observed in both NLC and Tg-GRK2 mice,
which accompanies progressive post-MI cardiac dysfunction
and LV remodeling as measured by echocardiography
(Figure 5B). In cardiac GRK2KO mice, there was an initial
lower glucose uptake response immediately after MI;
however, in vivo glucose uptake remained stable through-
out the study period, resulting in significantly higher
uptake compared with the NLC group at 6 to 8 weeks after
MI (Figure 5A). Interestingly, as in ARVMs (Figure 3C),
attenuated cardiac glucose uptake in vivo over time was
significantly attenuated with GRK2 overexpression, and
this worsened metabolic effect was most evident 1 to 3
weeks after MI (Figure 5A). These data show that higher
levels of myocardial GRK2 cause immediate post-MI
defects in glucose metabolism that are evident before LV
dysfunction appears; accordingly, Tg-GRK2 mice have
significantly worse cardiac function and remodeling long-
term after MI, whereas cardiac GRK2KO mice showed a
preserved glucose use, resulting in preserved cardiac
volume and function (Figure 5B and 5C).
Carboxyl Terminal Domain of G Protein–Coupled
Receptor Kinase 2 Improves Insulin Signaling in
Adult Cardiomyocytes
Our data indicate that excess GRK2 produces serious modi-
fications in cardiac glucose uptake and insulin signaling in
vivo and in vitro. Inhibition of GRK2 activity through the
carboxyl terminal domain of GRK2 (ARKct) has previously
rescued several models of HF.21,29 In light of the above data
showing, in particular, the protective role of myocardial
GRK2 loss on cardiac metabolism, we hypothesized that the
beneficial effect of ARKct in rescuing cardiac function
during HF could be due, at least in part, to a favorable effect
on cardiac metabolism. Indeed, transgenic mice with
cardiac ARKct expression (Tg-ARKct) have signifi-
cantly lower inhibitory IRS1 Ser307 phosphorylation in-
duced by insulin (Figure 6A), similar to data in cardiac-
specific GRK2 KO mice (Figure 4D). Therefore, ARKct
has the potential to enhance insulin signaling. We tested
this hypothesis by introducing ARKct in ARVMs via an
adenovirus (ADARKct). We found that ARKct expres-
sion restores and enhances Akt phosphorylation and a
downstream target of Akt, GSK3, compared with levels
found in ADGRK2- and ADGFP-treated myocytes, respec-
tively (Figure 6B and 6C).
Figure 5. Cardiac glucose uptake in post–myocardial infarction
(MI) mice. A, 18-Fluorodeoxyglucose (18-FDG) cardiac uptake in
nontransgenic littermate control (NLC), transgenic–G protein–
coupled receptor kinase 2 (Tg-GRK2), and cardiac-specific
GRK2 knockout (KO) mice under sham conditions and 1 to 8
weeks after MI. Top, Representative micro–positron emission
tomography images in which the infarct is clearly visible. Bot-
tom, Histogram quantifying 18-FDG uptake in myocardium
(*P0.05, Tg-GRK2 vs NLC; § P0.05, GRK2 knockout
[lsqb[KO] vs NLC; n12 per group). SUV indicates standardized
uptake values. B and C, Left ventricular diameter at diastole
(LVDd) and ejection fraction (EF) in NLC, Tg-GRK2, and
GRK2KO mice determined by echocardiography serially after MI
(*P0.01, Tg-GRK2 vs NLC; §P0.01, GRK2KO vs NLC; n12
per group).
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AAV6–Carboxyl Terminal Domain of G
Protein–Coupled Receptor Kinase 2 Gene Therapy
Prevents G Protein–Coupled Receptor Kinase
2–Mediated Defects in Cardiac Glucose
Metabolism Before the Rescue of Subsequent
Heart Failure
Next, we asked whether inhibiting GRK2 could lift the
negative effects of this kinase on in vivo myocardial insulin
signaling and measured myocardial glucose uptake and insu-
lin responses in post-MI rat hearts that expressed ARKct. To
do this, we injected AAV6-GFP or AAV6-ARKct into the
myocardium of rats during surgery to induce an MI, as we
have done previously.28 Then, we serially measured in vivo
glucose uptake in the heart via micro-PET, along with LV
dimension and function via echocardiography and LV cath-
eterization. As expected, our method of cardiac gene transfer
led to long-term and robust ARKct expression in the rat
heart (Figure IIA in the online-only Data Supplement).
AAV6-ARKct delivery compared with AAV6-GFP did not
produce any significant differences in cardiac function and
volume in sham-treated rats (data not shown); therefore, in
our data presentation, we show only 1 sham control group.
MI induces progressive dilatation and LV dysfunction
(Figure IIC and IID and Table I in the online-only Data
Supplement), and consistent with human and animal models
of HF, we found a progressive increase in myocardial GRK2
levels after MI (Figure IIB in the online-only Data Supple-
ment). Rats treated with AAV6-ARKct had significantly
improved post-MI cardiac function and significantly less
remodeling throughout the 12 weeks of study (Figure IIC and
IID and Table I in the online-only Data Supplement) with
respect to the AAV6-GFP group. When we assessed in vivo
Figure 6. Inhibition of G protein–coupled
receptor kinase 2 (GRK2) in myocytes
and myocardium restores normal insulin
(Ins) signaling and prevents defective in
vivo glucose uptake after myocardial
infarction (MI). A, Level of Ins-stimulated
phosphorylated (p) Ser307 in insulin
receptor substrate-1 (IRS1) immunopre-
cipitated (IP) from adult mouse ventricu-
lar myocytes isolated from nontrans-
genic littermate controls (NLC),
transgenic (Tg)-GRK2, or Tg–carboxyl
terminal domain of GRK2 (Tg-ARKct
mice) (*P0.01 vs NLC; n3; §P0.01,
Tg-ARKct vs NLC; n3 per group). IB
indicates immunoblot. B, Adult rat ven-
tricular myocytes (ARVMs) were infected
with adenovirus (AD) green fluorescent
protein (GFP), ADGRK2, or ADARKct.
Representative blots for p-Akt and total
(t) Akt are shown (*P0.01, fold increase
in activation, ADGRK2 vs ADGFP; n3;
**P0.01, fold increase in activation,
ADARKct vs ADGRK2 and ADGFP;
n3 per group). C, Representative West-
ern blot from ARVM whole lysate
infected as in A and stimulated with Ins
showing p-GSK3 and t-GSK3
(*P0.01, fold increase in activation,
ADGRK2 vs ADGFP; n3; **P0.01, fold
increase in activation, ADARKct vs
ADGRK2; n3). D, Global rat myocardial
in vivo glucose uptake evaluated by
micro–positron emission tomography in
sham and 1-, 3-, 6-, and 12-week
post-MI rats treated with AAV6-GFP or
AAV6-ARKct (*P0.05 vs AAV6GFP;
n8 per group). E, Rats 3 weeks after
MI and sham were euthanized 15 min-
utes after an intraperitoneal injection of
insulin (0.075 U/kg), and hearts were
removed. Plasma membranes were pre-
pared to evaluate GLUT4 levels as
shown in a representative blot (*P0.05
vs basal; §P0.05 vs basal; n3 per
group).
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glucose uptake after MI via micro-PET, we found that MI
caused an immediate defect in 18-FDG uptake in control
AAV6-GFP–treated rats; this metabolic abnormality was evi-
dent before any cardiac dysfunction or remodeling was found
(Figure 6D), a finding that was similar to the above studies in
mice (Figure 5). Interestingly, AAV6-ARKct–treated rats ac-
tually had normal myocardial glucose uptake 3 weeks after MI,
and this was significantly improved over post-MI GFP-treated
rats throughout the study (Figure 6D). To evaluate the potential
in vivo mechanism of the above PET results, we took a cohort of
3-week post-MI rats and challenged them with insulin to
measure GLUT4 membrane localization and found this to be
significantly blunted in GFP-treated rats. However, AAV6-
ARKct–treated animals had significantly improved insulin
responsiveness (Figure 6E).
Discussion
Our findings add significantly to the dynamic role of GRK2
in the pathogenesis of HF in that they uncover a new
mechanism by which upregulated GRK2 in the injured
myocardium promotes ventricular dysfunction. Importantly,
enhanced GRK2 activity not only negatively affects cardiac
contractile function after myocardial injury, but also causes
abnormal cardiac metabolism. Furthermore, GRK2 may rep-
resent a molecular link between the excessive neurohormonal
activation that follows cardiac stress and initiation of defects
in myocyte energy substrate use. Of note, our data reveal that
GRK2 inhibition via ARKct expression or its gene deletion
in myocytes corrects metabolic alterations observed during
the early stages of postischemic HF. This facilitates myocyte
use of glucose, which is a protective metabolic substrate, and
delays the development of HF.
As observed in our micro-PET studies, the modification in
cardiac glucose uptake is an early event after the induction of
MI. In particular, the initial increase is followed by a
progressive reduction, which is then accompanied by a
progressive cardiac dilation and reduced function. This be-
havior observed in NLC mice is significantly modified in
mice with altered GRK2 levels in myocytes. Enhanced GRK2
cardiac expression in Tg-GRK2 mice significantly reduces
protective myocyte glucose uptake, whereas cardiac-targeted
GRK2KO mice have preserved glucose uptake throughout
the 8-week post-MI period. Given the higher efficiency of
glucose in ATP production and the lower impact in oxidative
stress with respect to other substrates, we show that GRK2-
mediated pathogenesis in HF is mediated, at least in part,
through negative alterations in cardiac metabolism.
Our findings once again highlight the deleterious effects of
increased GRK2 levels that accompany myocardial ischemia,
and, most important, confirm the importance of identifying
strategies aimed specifically to reduce its activity in the heart
as potential HF therapy. Moreover, GRK2 inhibition with
ARKct, which has been demonstrated to rescue or prevent
animal models of HF and to improve contractile function of
failing human ventricular myocytes,28,35 has beneficial effects
that extend beyond the functional recovery of ARs and
contractility. Indeed, previous studies showed that GLUT4
overexpression improves cardiac function in mice with car-
diac insulin resistance.14,15 We demonstrate here that lower-
ing GRK2 during HF improves glucose uptake and delays the
development of the disease. We attribute at least part of the
improvement to restored insulin-stimulated GLUT4 mem-
brane translocation. G protein–coupled receptor kinase 2 also
represents the first identification of a molecule that represents
a nodal link between excessive neurohormonal stimulation
and metabolic abnormalities, supporting the hypothesis that
strategies aimed to preserve myocardial metabolism could be
beneficial in the treatment or prevention of HF.
Insulin signaling is known to be protective in the heart by
inhibiting apoptosis and oxidative stress36; it is also an
important regulator of cardiac mass.37 These effects are
mediated primarily by activation of PI3K-Akt and inhibition
of GSK3.38 On the basis of the results of this study,
injury-induced increases in GRK2 within the cardiomyocyte
may increase oxidative stress, which expands our mechanistic
understanding of why Tg-GRK2 mice progress more rapidly
to HF. Therefore, GRK2 clearly has effects in the myocyte
that extend beyond G protein–coupled receptor–mediated
functions, improving our mechanistic understanding of the
pathological nature of GRK2 in the heart.
Of interest, recent studies have described a correlation
between insulin resistance and increased levels of GRK2 in
pathological conditions. In particular, Garcia-Guerra et al34
have recently found that overexpression of either GRK2 or
the kinase-dead mutant reduces insulin sensitivity in myo-
blasts and adipocytes, and that finding was consistent with
other studies25,31 that suggested that a kinase-independent
mechanism was involved, possibly by sequestering molecules
involved in insulin signaling such as Gq/11, Akt, and IRS1.
However, our data demonstrate for the first time that the
catalytic activity of GRK2 is fundamental and a requirement
in postischemic cardiac metabolic alterations, in particular,
the dampening insulin signaling.
The finding that Ser307 of IRS1 is a target for GRK2
phosphorylation in cardiomyocytes significantly increases the
overall knowledge about the regulation of insulin signaling in
physiology and pathology. Several serine residues within
IRS1 are involved in the physiological mechanism of IRS1
inhibition; however, Ser307 has specific properties and char-
acteristics that make it particularly interesting as a target of
GRK2. This site is found proximal to the IRS1 phospho-Tyr
binding domain, and Ser307 phosphorylation rapidly reduces
its affinity for binding to the insulin receptor,33 a process that
resembles AR desensitization. Thus, GRK2 appears to
directly modulate signaling through this non–G protein–
coupled receptor and participates in the physiological regu-
lation of insulin signaling. Accordingly, GRK2 inhibition
reduces insulin-mediated Ser307 phosphorylation and im-
proves signaling, and as a result can improve glucose uptake
and insulin resistance in the injured cardiomyocyte. Indeed,
elevated levels of phospho-Ser307 of IRS1 have been ob-
served in animal models of insulin resistance, and the
equivalent Ser312 site in human IRS1 has been demonstrated
to be hyperphosphorylated in insulin-resistant subjects.39,40
Therefore, our findings can hypothetically be extended be-
yond the heart, and suggest that ARKct gene therapy could
be used for the possible treatment of reduced skeletal muscle
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and liver glucose uptake, as is observed in type II diabetes
mellitus.
Overall, our data show that GRK2 inhibition clearly delays
the reduction in glucose uptake and protects insulin signaling
in the heart, preserving cardiac dimension and function.
These data support the novel hypothesis that part of the
therapeutic effect of GRK2 inhibition in HF includes correc-
tion of abnormal cardiac metabolism.
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CLINICAL PERSPECTIVE
A large number of studies have demonstrated that the increased level of G protein–coupled receptor kinase 2 (GRK2) seen
in injured myocardium has deleterious effects on the progression of heart failure (HF). Importantly, GRK2 lowering is
associated with improved cardiomyocyte signaling and function in failing human hearts mechanically unloaded with assist
devices. However, the mechanisms through which GRK2 promotes HF, or why its inhibition is therapeutic has not been
fully elucidated. Interestingly, therapies targeting the neurohormonal axis, such as -blockers, can attenuate cardiac
remodeling and improve prognosis in patients with HF, and these drugs can significantly decrease GRK2 in the heart. On
the other hand, agents aimed at directly increasing cardiac contractility have failed. Thus, it appears that GRK2 lowering
and inhibition, which improve contractility, must have additional effects on pathological components of HF development
to account for the overwhelming positive effects seen in various animal models. The present study provides the first
evidence that there is a close relationship between GRK2 activity and unfavorable modifications of cardiac metabolism,
including insulin resistance and a loss of glucose uptake that can occur after ischemic injury and through the progression
to HF. Indeed, we have identified IRS1 as a novel substrate of GRK2 kinase activity that can attenuate insulin signaling
in the myocyte. These data also demonstrate that insulin resistance and defective glucose uptake appear in the early stages
of HF, suggesting the use of therapies aimed at restoring correct metabolic substrate utilization in the myocyte as soon as
possible after ischemic injury. In this scenario, lowering GRK2, which is known to be upregulated acutely after myocardial
injury, appears to be a feasible and exciting approach to maintain metabolic homeostasis in the myocyte, which may
contribute significantly to preventing the development of subsequent ischemic HF.
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Supplementary Methods  
Isolation and adenoviral infection of ventricular cardiomyocytes for in vitro experiments. 
Adult rat ventricular myocytes (ARVMs) and adult mouse ventricular myocytes (AMVMs) were 
isolated from 12 week old Sprague/Dawley rat or mouse hearts, respectively, by a standard 
enzymatic digestion procedure and cultivated as described 
1
. Rat neonatal ventricular myocytes 
(NRVMs) were isolated as previously described 
2
. Adult and neonatal myocytes were treated 
with various adenoviruses as previously described 
2
.  Cells were generally used for experiments 
48hrs post infection.  
 
Surgical induction of MI.  All animal procedures and experiments were performed in 
accordance with the guidelines of the Institutional Animal Care and Use Committee of Thomas 
Jefferson University.  Mice at 8-10 weeks of age were used for MI experiments in which left 
anterior descending (LAD) coronary artery ligation was carried as described previously 
3, 4
. For 
rat MI, 12 week old Sprague/Dawley rats were used and a previously described model of 
cryoinfarction was used 
5
.  Briefly, anesthetized adult male (175-200g) rats were intubated and 
mechanically ventilated and anesthesia was maintained using a 2% isoflurane (v/v) oxygen 
mixture.  Cryothermia was applied by use of three freeze cycles of 1 min each that was 
interrupted by one minute thawing intervals. Soon after induction of MI, myocardial gene 
transfer was achieved by intra-myocardial direct injection as previously described 
5
.   
 
In vivo cardiac glucose uptake measurement by microPET.   Imaging was performed in the 
prone position using an animal microPET scanner (Inveon Dedicated PET, Siemens Medical 
Solutions Inc).  Animals were starved 2 hrs before the study to normalize glucose and insulin 
levels and anesthetized using 1.5% isoflurane throughout the imaging.  After starting image 
acquisition, animals were injected with an average of 30 MBq of 18 FluorDeoxyGlucose (18-
FDG) in the tail vein.  The dynamic PET acquisition continued for 120 minutes in listmode 
format.  Images were reconstructed as previously described 
6
.  FDG uptake in the myocardium 
was semiquantitatively assessed by evaluating the standardized uptake value (SUV, activity 
concentration/injected dose/body weight).  Regions of interest (ROI) were obtained by drawing 
area of equal size on the myocardium by excluding the infarcted and non uptake area and SUV 
calculated from an averaged image of the last 30 min (6 frames) of the FDG scan using the 
following equation:  voxel value within ROI (Mbq/ml)/activity injected (Mbq)/body weight 
(mg).  Data are expressed as maximal value of SUV in the last 30 min of scanning (SUVmax). 
 
Glucose uptake in ARVMs.  Glucose uptake assay was performed as previously described with 
some modifications 
7
.  Assays were performed in triplicate in 12-well (22 mm in diameter) 
laminin-coated tissue culture plates.  Cells were washed twice with 1 ml of glucose-free DMEM 
and then 1 ml of glucose-free DMEM (37 °C) containing insulin or PBS, 1 mM pyruvate and 
0.1% BSA was added.  40 min later 10 μl of a 2-deoxyglucose mix containing 130 μl of glucose-
free DMEM, 15 μl of 100-mM 2-deoxyglucose solution, and 5 μl of 1μCi/μl [3H]2-deoxyglucose 
was added. After 30 min the cells were lysed in 500 μl of NaOH (1 M) for 20 min at 37 °C.  A 
400-μl aliquot of the lysed extract was counted to determine the specific activity of [3H] 2-
deoxyglucose and normalized the result to protein concentration (Pierce). Data were expressed as 
cpm/mg of protein. 
 
In-vitro kinase assay using FLAG-IRS1.  NRVMs were infected using adenovirus encoding for 
the expression of either Flag-tagged wild-type IRS1 or the IRS1-S307A mutant.  IRS1 was 
immunopreciptated from whole cell lysates using a Flag antibody conjugated to agarose beads 
(Sigma).  Equal amounts of wild-type or mutant IRS1 were used as substrate in the in-vitro 
kinase assay.  Phosphorylation reactions were conducted in a 50ul reaction volume in kinase 
buffer that contained 25mM Tris (pH7.5), 10mM MgCl2, 2mM DTT, 5mM α-Glycerophosphate, 
and 0.1mM Na3VO4 and 0.2mM ATP. GRK2-stimulated phosphorylation was initiated by the 
addition of 250ng purified GRK2 (Invitrogen) and 100ng Gβ subunits (Calbiochem).  Reactions 
were carried out for 30min at 30
o
C and stopped by the addition of 50ul of 2x sample loading dye.  
Samples were heated for 5 min at 95
o
C, mixed and briefly centrifuged to pellet the flag beads. 
30ul of each reaction was loaded onto a 4-20% Tris-Glycine gel and following electrophoresis 
the proteins were transferred to nitrocellulose for western blotting.  The phosphorylation state of 
IRS1 was probed using a site specific antibody to Ser307 (Millipore) and the amount of total 
IRS1 used in the assay was detected by blotting for Flag (Sigma).  For quantification the amount 
of phosho-Ser307 was normalized to total IRS1 for a given reaction. 
In-vitro Kinase Assay using purified GST-IRS1. A GST-IRS1 fusion protein consisting of 
mouse IRS1 amino acid residues 108-516 was used as the substrate for reconstitution kinase 
assays.  This murine IRS1 fragment (108-516) was amplified by PCR and subcloned into pGEX-
2T using standard molecular biological techniques and results were confirmed by sequencing.  
BL21DE3 cells transformed with the plasmid were induced for 3 hrs with 1mM IPTG (Sigma) 
and the bacterial lysate was prepared and incubated with glutathione agarose to pulldown GST-
IRS1.  The beads were washed twice with lysis buffer and then 2 more times with kinase buffer 
before use in assays.  Phosphorylation reactions were conducted in a 50ul reaction volume in 
kinase buffer that contained 25mM Tris (pH7.5), 10mM MgCl2, 2mM DTT, 5mM -
Glycerophosphate, and 0.1mM Na3VO4 and 0.2mM ATP. GRK2-stimulated phosphorylation was 
initiated by the addition of 250ng purified GRK2 (Invitrogen) and 100ng of purified G 
complex (Calbiochem) to ensure maximal activation of GRK2.  Reactions were carried out for 
40min at 30
o
C and stopped by the addition of 10ul of 6x sample loading dye.  Samples were 
heated for 5 min at 95
o
C, mixed and centrifuged to pellet the agarose beads. 30ul of each 
reaction mixture was loaded onto a 4-20% Tris-Glycine gel and after electrophoresis the proteins 
were transferred to nitrocellulose for western blotting. The phosphorylation of IRS1 was probed 
using a site-specific antibody to Ser307 (Millipore) and the amount of total IRS1 used in the 
assay was detected by blotting for GST (SantaCruz).  For quantification the amount of phospho-
ser307 was normalized to total IRS1 for each reaction. 
 
Echocardiography.  To measure global cardiac function, echocardiography was performed 1, 3, 
6 and 8 week post-MI in mice and 3, 6 and 12 week post MI in rats by use of the VisualSonics 
VeVo 770 imaging system with a 710 scanhead in anesthetized animals (2% isoflurane, v/v).  
The internal diameter of the LV was measured in the short-axis view from M-mode recordings in 
end diastole and end systole and ejection fraction (EF) and fractional shortening (FS) were 




Catheter-based in vivo Hemodynamic Measurements.  Cardiac function was measured at the 
appropriate times in mice and rats using a 2 F pressure catheter (SPR-320; Millar instruments, 
Houston, Texas).  The pressure transducer was placed into the LV cavity through the right 
carotid artery and the right external jugular vein was cannulated with a P-10 catheter (Becton 





Plasma membrane isolation, immunoblotting and immunoprecipitation.  For plasma 
membrane isolation, cells were homogenized in buffer containing 25 mM Tris-HCl (pH 7.5), 5 
mM EDTA, 5 mM EGTA, 1mM phenylmethylsulfonyl fluoride, 2 μg/ml each leupeptin and 
aprotinin.  In experiments that required detection of phospho-proteins lysis buffers also 
contained phosphatase inhibitors (Sigma). Intact cells and nuclei were moved by centrifugation 
at 1,000 × g for 15 min.  The collected supernatant was further subject to a centrifugation at 
38,000 × g for 1 hour.  The pellet was resuspended in lysis buffer (1% Nonidet P-40, 
10%glycerol, 137 mM NaCl, 20 mM TrisHCl (pH 7.4), 1 mM phenylmethylsulfonyl fluoride, 20 
mM NaF, 1 mM sodium pyrophosphate, 1 mM sodium orthovanadate, and 2 μg/ml each 
aprotinin and leupeptin) and used as plasma membrane fraction, and the supernatant was used as 
the cytosolic fraction.  Whole cell lysates were prepared in RIPA buffer (50mM Tris-HCl (pH 
7,5), 150mM NaCL, 1%NP-40, 0.25% deoxycholate, 9.4mg/50ml sodium orthovanadate, 1% 
sodium dodecyl sulphate).  Protein concentration was determined using BCA assay kit (Pierce).  
For immunoprecipitation (IP), endogenous IRS1 from whole cell lysates was IP’d with IRS-1 
antibody (Cell Signaling) and protein A/G conjugated to agarose beads (Santa Cruz).  Samples 
were rotated overnight at 4°C then centrifuged at 12,000×g for 5 min.  IP’s were washed twice 
with lysis buffer, twice with  phosphate buffered saline, and suspended in 1× SDS gel loading 
buffer.  Clarified lysates, membrane proteins, or immunocomplexes were resolved by SDS-
PAGE on Tris-Glycine gels and transferred to a nitrocellulose membrane.  GLUT4 (1:1000, Cell 
Signaling), Total IRS1 (1:1000 Cell Signaling), GRK2 (1:5000, Santa Cruz), pIRS1 ser307 
(1:1000, Millipore), pIRS1 Tyr 612 (1:1000, Sigma), pAkt (1:1000, Cell Signaling), and Total 
Akt (1:1000, Cell Signaling) were visualized after incubation with fluorescent secondary 
antibodies using the Odyssey imaging system from LiCor. Quantification of band density was 
determined using the built-in densitometric software application from LiCor. 
 
Immunofluorescence. ARVMs were plated on glass-bottom dishes (FluoroDish, WPI) pre-
coated with laminin (Invitrogen).  Following treatment with insulin, standard immunostaining 
techniques were performed. Briefly, cells were fixed for 15 min using 4% PFA, blocked with 1% 
BSA/PBS and incubated with primary antibodies against IRS1 (Abcam, ab52167) and GRK2 
(Santa Cruz Biotechnology, sc-13143) at 1:50 dilutions. Secondary antibodies conjugated to 
Alexa Fluor488 and Alexa Fluor568 (Invitrogen), were used at 1:200 dilutions.  Images were 
obtained using Olympus FluoView 500 laser scanning confocal microscope.  Control images to 



































Sham 3 8 6527±232 15809±573 -8698±302 -10980±257 
 6 8 6423±126 15842±248 -8421±214 -10422±203 
 12 8 6203±268 15362±185 -8551±252 -10322±233 
AAV6GFP 3 8 6246±796 13658±941 -6299±706 -6889±513
*
 










AAV6βARKct 3 8 6306±803 14131±714 -7171±886 -7581±606* 










Supplementary Table 1. Hemodynamic measurements in post MI rats. Data are presented as mean 
± standard error. Sham: Control group. AAV6GFP: post MI treated with AAV6GFP. AAV6βARKct: 
post MI treated with AAV6βARKct. dp/dtmax: maximum rate of rise of LV pressure；dp/dtmin: 
maximum rate of fall of LV pressure (* P<0.05 vs Sham; § P< 0.05 vs AAV6GFP). Shown is data at 
baseline (basal) and after administration of the AR agonist isoproterenol (Iso 333 ng/Kg – 10 min.).  
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Supplementary figure legends 
Supplementary Figure 1. (A) Immunofluorescence assay showing translocation of GRK2 (red) 
and IRS1 (green) from cytosol to the plasma membrane in response to Insulin (Ins) treatment 
(0.1 μM for 10 min).  GRK2 and IRS1 co-localization at the plasma membrane is shown in the 
merged image (yellow).  This figure is representative of 3 independent experiments. (B) GRK2 
co-immunoprecipitates with IRS1. IRS1 was immunoprecipitated from whole lysate of ARVMs 
with or without Ins stimulation. This figure is representative of 3 independent experiments (C) 
GRK2 cannot phosphorylates IRS1mt. Western blot of GRK2-stimulated Ser307 
phosphorylation of wild-type or mutant IRS1. Representative blot from 3 independent assays is 
shown (D) ARVMs infected with ADGRK2 (wild-type, WT), ADGFP or a kinase-dead, 
dominant-negative GRK2 (ADGRK2DN = GRK2-K220R) and stimulated with Ins (0.1 μM for 
10 min) were analyzed for Tyr 612 phosphorylation (activating) of IRS1. A representative blot 
for pTyr 612 IRS1 and total IRS1 and densitometric analysis of three independent experiments is 
shown in the lower panel (* P<0.05, fold of activation, ADGRK2 vs ADGFP and ADGRK2DN, 
n=3). (E) NRVMs were co-infected with either ADIRS1wt or ADIRS1 mutant Ser307Ala (mt) 
in addition to ADGFP or ADGRK2 and stimulated with Ins as above. Representative blots for 
GLUT4 and NKA are shown (§, P<0.01, fold activation vs ADGRK2+ADIRS1wt, n=3). 
 
Supplementary Figure 2. (A) Representative western blot showing βARKct transgene 
expression in the heart 3 weeks post surgery and gene delivery compared to a sham operated 
animal. (B) GRK2 up-regulation during HF progression evidenced by western blot in 3 and 6 
week post-MI rat hearts compared to sham animals (* P<0.05 vs Sham, n=6). (C) Cardiac 
dimensions evaluated by echocardiography in Sham, AAV6GFP, AAV6βARKct treated Rats at 
2, 6 and 12 weeks post-MI. Representative M-mode images at the top and histogram showing 
calculated LV diameter at diastole at the bottom (* P< 0.01 vs AAV6βARKct and Sham, n=12).  
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